Sum Krishnan

Suma Krishnan has over 25 years of drug development experience and has delivered on multiple gene therapy programs from discovery to the clinic as Head of Therapeutics at Intrexon Corporation (NYSE: XON). Previously, she led the discovery, development, and approval of Vyvanse (a blockbuster drug to treat ADHD) as SVP, Product Development at New River Pharmaceuticals. Prior to that, Ms. Krishnan advanced approval of Adderall XR and Fosrenol at Shire. She began her career as a discovery scientist for Janssen Pharmaceuticals, Inc. Ms. Krishnan has numerous publications and several U.S. patents. She received her Master of Science in Organic Chemistry from Villanova University, an M.B.A. from Institute of Management and Research, and an undergraduate degree in Organic Chemistry from Ferguson University.